Xlife Sciences AGXSWX:XLS -11.06%50 Pretax Margin % is 29,944.30% as of Dec. 2025, which is 6425% above its 10-year median of 458.91. GuruFocus rates XSWX:XLS with a GF Score™ of 50/100 and a GF Value™ of CHF7.30 (Significantly Overvalued). The stock has 13 warning signs investors should review. Among 947 Biotechnology companies, Xlife Sciences AG ranks worse than 93.35% on this metric.
The historical rank and industry rank for Xlife Sciences AG's Pretax Margin % or its related term are showing as below:
XSWX:XLS'
s Pretax Margin % Range Over the Past 10 Years
Min: -11585.46 Med: 458.91 Max: 6599.88
Current: -11585.46
XSWX:XLS's Pretax Margin % is ranked worse than 93.35% of 947
companies
in the Biotechnology industry
Industry Median: -90.63
vs XSWX:XLS: -11585.46
Xlife Sciences AG (XSWX:XLS) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Xlife Sciences AG Pretax Margin % Related Terms
Xlife Sciences AG Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a Pretax Margin % of 29,944.30% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Xlife Sciences AG and its competitors. This is 6425% above median its historical median of 458.91. According to the industry distribution chart, Xlife Sciences AG ranks #884 out of 947 companies in the Biotechnology industry, placing it in the top 93.3%.
Is Xlife Sciences AG's Pretax Margin % too high?
Xlife Sciences AG's current Pretax Margin % of 29,944.30% is 6425% above median its 10-year median of 458.91. Based on the distribution chart, Xlife Sciences AG ranks #884 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #884 out of 947 companies for Pretax Margin %. This places Xlife Sciences AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Pretax Margin % is 29,944.30%, which is 6425% above median its own 10-year median of 458.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.30, compared to a current price of CHF20.90 — trading 186.3% above its estimated fair value. The current Pretax Margin % is 29,944.30%, which is 6425% above median its 10-year median of 458.91. Xlife Sciences AG's overall GF Score™ is 50/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Pretax Margin % is 29,944.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF20.90 is trading 186.3% above its estimated GF Value™ of CHF7.30.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Pretax Margin %: 29,944.30% (6425% above median its 10-year median of 458.91)
GF Value™: CHF7.30 vs. price of CHF20.90 (186.3% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score
Get the complete analysis for XSWX:XLS
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
